Merck Signs a Clinical Trial Collaboration with FLX Bio, for a Combination Therapy

 Merck Signs a Clinical Trial Collaboration with FLX Bio, for a Combination Therapy

Merck Signs a Clinical Trial Collaboration with FLX Bio, for a Combination Therapy

Shots:

  • The agreement involves assessing of FLXBio’s  FLX475 candidate with Merck’s Keytruda (pembrolizumab) in the ongoing P-I/II as an anti-PD-1 therapy in patients with multiple types of cancer
  • The study will evaluate efficacy, safety & tolerability of FLX475 as a monothx and in combination with Keytruda in various centers including the US, Australia and Asia
  • FLX475 PO is a novel inhibitor of CCR4, while promoting anti-tumor immune response

Click here to read full press release/ article | Ref: FLX Bio | Image: Life raft group

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post